In a significant leadership addition, Sun Pharmaceutical Industries Ltd. has appointed Shaik Barak Tulla as Senior Vice President, marking a decisive step in bolstering its commercial strategy and innovation-led growth. With over 25 years of experience in the pharmaceutical industry, Tulla brings a track record of transformative leadership, strategic foresight, and people-first execution.
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla, where he led one of the largest business clusters with a P&L responsibility of INR 1800 Cr ($225 million) and oversaw seven business units and 2,500 employees. Reporting directly to the CEO of Cipla’s One India Business, Tulla’s leadership saw the Acute Cluster rise in both profitability and therapy area dominance, notably in respiratory, anti-infectives, and critical care.
Tulla was the driving force behind Cipla’s flagship brands like Foracort, Azee, and Mucinac, and purpose-driven campaigns such as Berok Zindagi, blending patient-centric approaches with digital and AI-powered innovations. His tenure was marked by some of the industry’s lowest attrition rates and a high concentration of award-winning performers, thanks to his expertise in Sales Force Effectiveness (SFE) and people development.
He is widely recognized for his digital acumen, including the first-time utilization of AI-based strategic levers, influencer marketing, and communication innovation in pharma marketing. His efforts have earned accolades from prestigious forums like IHW Council, Digital Health Summit, and the FLAME Awards.
Also Read :- Himanshu Gaur Joins Medanta | A Strategic Leap in Healthcare Supply Chain Excellence
An alumnus of top business institutions including ISB, INSEAD, IIM Ahmedabad, and Singapore Management University, Tulla is known as a maximizer leader—one who scales large business clusters with resilience, divergent thinking, and customer-centric strategy. His career spans expertise across acute and chronic segments, especially in critical care, respiratory, GI, derma, pain, VMN, and hospital-based therapies.
With a proven ability to drive top-line growth, transform legacy businesses, and optimize operations through robust supply chain and inventory strategies, Tulla’s arrival at Sun Pharma signals a renewed focus on commercial excellence, innovation, and global leadership in the evolving healthcare landscape.
Sun Pharma’s move to onboard a dynamic and purpose-led leader like Shaik Barak Tulla underscores its commitment to delivering impactful healthcare outcomes while scaling new frontiers in the global pharmaceutical arena.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
